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2Abstract
Aim. Sexual dysfunction, common in schizophrenia, may be further exaggerated by
antipsychotics, especially those of First Generation (FGAs), and antidepressants, such
as Selective Serotonin Reuptake Inhibitors (SSRs). Mirtazapine, an antidepressant
characterised by its different action mechanism compared with that of the majority of
other antidepressants, may improve SSRI-induced sexual dysfunction in patients with
depression. It is unknown, however, whether mirtazapine improves sexual functioning
in schizophrenia.
Methods. This study randomly assigned FGA-treated patients with schizophrenia to
receive either an add-on mirtazapine (n = 20) or a placebo (n = 19) for six weeks.
Sexual functioning was prospectively measured using five relevant items from the UKU
side-effect rating scale (UKU-SERS).
Results. Orgasmic function significantly improved with statistical significance in the
mirtazapine group (p=0.03), with no changes in any other sexual functions in either
group.
Conclusion. We conclude that mirtazapine does not worsen sexual functioning in FGA-
treated patients with schizophrenia and may relieve orgasmic dysfunction.
Keywords: mirtazapine, orgasmic dysfunction, sexual dysfunction, RCT, FGA,
schizophrenia
The trial was registered with www.controlled-trials.com (no. ISRCTN00721331)
3Background.
Sexual dysfunction is a common problem in patients with schizophrenia. Estimates for
the prevalence of decreased sexual desire reach as high as 54%, while difficulties with
achieving orgasm reach 42% (1). Erectile and ejaculatory dysfunction, respectively,
may be observed in 48.1% and 64.2% of schizophrenic men (1). Sexual dysfunction
may be due to the disease itself, resulting from a number of physiological and endocrine
abnormalities (2). Some researchers assume that negative symptoms, especially
anhedonia and avolition, may impair an individual’s ability to enjoy sexual life (3, 4).
Antipsychotics, the primary psychopharmacological treatment for schizophrenia, may
also induce sexual adverse effects, mainly by increasing the plasma prolactin level (4).
This is especially true for first-generation antipsychotics (FGAs), which cause sexual
dysfunction more often than do second-generation antipsychotics (SGAs) (5, 6). This
difference may be due to SGAs’ greater affinity for serotonin 5-HT2 receptors than for
D2 receptors which results in the reduced incidence of hyperprolactinemia (6).
Antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin–
norepinephrine reuptake inhibitors (SNRIs) cause sexual dysfunction in approximately
one-third of patients with depression (8). These drugs, especially SSRIs, are widely
used to alleviate the negative or depressive symptoms of schizophrenia (9). Combined
with antipsychotics, they may further worsen sexual functioning in patients with
schizophrenia.
Approaches aiming to diminish sexual dysfunction in schizophrenia include, among
others, antipsychotic dose reduction, switching to a prolactin sparing antipsychotic or
using adjunctive medication (10). Among adjunctive medications, addition of
4aripiprazole (11), or a phosphodiesterase-5 inhibitor (12) has shown positive results, but
evidence is currently far from convincing.
Another possible strategy for improving sexual functioning in schizophrenia may be
add-on treatment with mirtazapine, an antidepressant that carries a seemingly low risk
of sexual dysfunction in patients with depression (13). Hypothetically, mirtazapine, an
antidepressant with a serotonin 5HT-2a/c receptor blocking properties added to a pure
D2 receptor blocker (i.e., FGA), may emulate the receptor profile of an SGA and, thus,
improve sexual functioning (14).
Aims.
This study aimed to determine whether an add-on mirtazapine improves the FGA-
associated sexual dysfunction in patients with schizophrenia or schizoaffective disorder.
Methods
Subjects
The eligibility criteria for this study have been described elsewhere (11). In brief, the
study population comprised patients with schizophrenia or schizoaffective disorder who
remained highly symptomatic despite adequate therapy with FGAs in fixed doses for at
least six weeks. Patients were recruited from the in- and outpatient psychiatric units in
Petrozavodsk, Russian Federation. All patients provided written informed consent, and
the study was carried out in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines.
Study design
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(RCT). After a one-week placebo run-in period, patients were randomized to receive
double-blind treatment with either an add-on 30-mg daily dose of mirtazapine
(mirtazapine group) or an add-on placebo (placebo group) for six weeks. The doses of
currently prescribed FGAs remained unchanged during the study period.
Efficacy evaluation
For this sexual dysfunction branch of the study, the primary measure of efficacy was the
change in five items for sexual dysfunction taken from the UKU side effect rating scale
(UKU-SERS), clinician rated version (12). These items included Increased Sexual
Desire, Diminished Sexual Desire, Erectile Dysfunction, Ejaculatory Dysfunction and
Orgasmic Dysfunction. Assessments were made at weeks zero, one, two, four and six.
Statistical analysis
Data were analysed using the independent sample t-test for between-group changes or
the paired sample t-test for within-group changes (means and standard deviation in both
cases). Pearson’s correlation analysis was performed to examine correlations between
changes in efficacy measures and other clinical parameters, such as the Positive and
Negative Syndrome Scale (PANSS) negative, positive, general and total (sub-) scales,
as well as the Calgary Depression Scale for Schizophrenia (CDSS). All tests were two-
tailed, and a p < 0.05 was considered statistically significant. All analyses were
performed using SPSS for Windows, version 19.0.
Results
6Study population
A detailed description of the study population appeared elsewhere (11). Among the 41
patients randomised, 40 completed the trial and data of 39 patients were analysed. At
baseline, the treatment groups did not differ in terms of demographic or clinical
characteristics, with the exception of higher PANSS positive scores in the mirtazapine
group (for further details, see Joffe et al. (11).
UKU-measured sexual side effects of antipsychotics
At baseline, the treatment groups did not differ statistically significantly on any of the
UKU-measured symptoms of sexual dysfunction (Table 1).
After six weeks of double-blind treatment, the mirtazapine group showed a statistically
significant improvement on the orgasmic dysfunction item of UKU-SERS (p=0.03). No
other UKU-SERS parameters changed for either group. Between-group analysis did not
reveal any differences between treatment with mirtazapine or the placebo.
Correlation between changes in clinical parameters and symptoms of sexual
dysfunction
In the mirtazapine group, the improvement in orgasmic dysfunction tended to correlate
with an improvement in depressive scores on CDSS (r=0.48, p=0.05). No other
statistically significant correlations were found in either group.
Discussion
This trial used a randomised, double-blind, placebo-controlled design to assess the
efficacy of adjunctive mirtazapine in alleviating symptoms of sexual dysfunction in a
7population of FGA-treated patients with schizophrenia. Mirtazapine was well-tolerated
with no drop-outs due to adverse events. The data analysis from the MITT population
revealed a favourable effect from mirtazapine on orgasmic dysfunction. This effect
tended to correlate with a mirtazapine-induced improvement in depressive symptoms.
To the best of our knowledge, no other published studies on the effects of mirtazapine
on sexual dysfunction in schizophrenia exist. According to the findings from studies on
Major Depressive Disorder, mirtazapine itself may carry some sexual side effects,
although estimates of their prevalence remain lower than for the majority of other
antidepressants (13). However, in some studies mirtazapine demonstrated favourable
effects on sexual dysfunction in depressed patients (14). Mirtazapine has also repeatedly
accompanied improvements in several symptoms of sexual dysfunction caused by
SSRIs (15, 16), although these data remain equivocal (17).
Sexual dysfunction in schizophrenia appears as a phenomenon with a complex
aetiology. It may result from the negative and depressive symptoms of the disease or
emerge as an antipsychotic-induced adverse effect. In previous studies, mirtazapine
added to FGAs (11, 18) or SGAs (19) improved the negative symptoms of
schizophrenia. Mirtazapine may also carry an antidepressive effect in the treatment of
schizophrenia-related depression (20). Thus, the favourable effect of mirtazapine on
sexual dysfunction found in this study may be indirect, that is mediated through an
improvement of negative or depressive symptoms or both.
The favourable effect of mirtazapine on orgasmic dysfunction may be explained by its
receptor profile. Some evidence suggests that both the inhibition of 5-HT2 receptors and
the stimulation of the 5-HT1A receptor facilitate sexual functioning (22). This evidence
mainly derives from clinical trials where a 5-HT2 inhibitor cyproheptadine (23) and a
8partial 5-HT1A receptor agonist buspirone (24) reduced SSRI-induced sexual
dysfunction. As a 5-HT2 antagonist and 5-HT1a indirect agonist, mirtazapine may
mitigate orgasmic dysfunction relying on these mechanisms. Mirtazapine can also
diminish the antipsychotics-induced hyperprolactinemia via the increase of dopamine
release resulting from the 5-HT2a/c receptor blockade. As an alpha-2 receptor
antagonist, mirtazapine shares this feature with yohimbine, a drug with an established
efficacy in treating erectile and orgasmic dysfunction in men (25).
The limitation of this study is that, as a secondary branch of an RCT, it was not
designed specifically to investigate the effects of mirtazapine on sexual dysfunction.
That is, we did not select patients for the presence of sexual dysfunction and the UKU-
measured sexual dysfunction served as a secondary outcome. Furthermore, we didn’t
measure the development of the mirtazapine’s effect on sexual dysfunction, i.e.
measurements were only made on baseline and endpoint, without any measures on
intermediate time-points. The authors assume that the possible beneficial effect of
mirtazapine on sexual dysfunction has emerged only partially due to the short duration
of the study. Presumably, long term treatment would provide better insights in the
potential effects of mirtazapine on sexual dysfunction. Another limitation of this study
lies in its relatively small sample size. The scale used to measure sexual dysfunction
was clinician-rated, although patients’ rating may differ from those of clinicians’,
especially for sexual dysfunction. Future studies should comprise larger populations,
should be of longer duration and focus on patients with schizophrenia experiencing
sexual dysfunction.
Conclusion.
9We conclude that mirtazapine added to FGAs does not worsen sexual functioning and
may serve as an alternative to SSRIs (and, possibly, to SNRIs) when a clinician
considers antidepressant treatment for a patient with schizophrenia. Mirtazapine may
improve orgasmic dysfunction, presumably through both direct pharmacodynamic (the
noradrenergic and specific serotoninergic receptor affiliation) and indirect (those
mediated by improved negative and depressive symptoms) mechanisms. Studies with a
larger sample size and specifically designed to investigate the influence of adjunctive
mirtazapine on sexual dysfunction in patients with schizophrenia are warranted.
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Table 1. UKU-SERS1-measured sexual dysfunction in FGA2-treated patients with schizophrenia
during a six-week double-blind treatment period with an add-on mirtazapine or placebo
Parameter
Baseline Change from week zero to week six3
Mirtazapine
group
(n = 20)
Placebo
group
(n = 19)
Mirtazapine
vs placebo
group
Mirtazapine
group
Placebo
group
Mirtazapine
vs placebo
group
Increased
sexual
desire
0.24 (0.44)4 0.25
(0.58)
t = 0.38
p=0.71
0.19
t = 1.00
p=0.32
0.06
t = 0.43
p=0.67
t = -1.09
p=0.29
Diminished
sexual
desire
2.05 (1.03) 1.5
(0.93)
t = 1.48
p=0.15
-0.05
t = -0.37
p=0.72
0.06
t = -0.56
p=0.58
t = 1.8
p=0.08
Erectile
dysfunction
2.29 (0.76) 1.56
(0.73)
t = 1.01
p=0.33
0.14
t = 1.00
p=0.36
-0.22
t = -1.50
p=0.17
t=1.25
p=0.23
Ejaculatory
dysfunction
2.50 (0.70) 1.40
(0.55)
t = 0.57
p=0.59
0.50
t = 1.00
p=0.5
0.20
t = 1.00
p=0.37
t = 1.28
p=0.26
Orgasmic
dysfunction
1.24 (0.97) 1.28
(0.75)
t = -0.15
p=0.88
0.47
t = 2.42
p=0.03
0.11
t = 0.69
p=0.49
t = -1.81
p=0.08
UKU sexual
dysfunction
module,
total score
8.32 (2.83) 5.99
(1.79)
t = 1.65
p=0.14
1.25
t = -1.46
p=0.5
0.21
t = -2.45
p=0.07
t = 0.80
p=0.43
1 UKU-SERS, UKU side effects rating scale
2 FGA, first-generation antipsychotic
3 A positive value indicates an improvement.
4 Data displayed as mean (standard deviation).
